Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine whether there is a causal relationship between insulin resistance and/or glucose intolerance in the development of a defect incretin effect.
| Condition | Intervention |
|---|---|
|
Insulin Resistance Glucose Intolerance |
Drug: Dexamethasone |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Single Group Assignment Masking: Open Label |
| Official Title: | Is Insulin Resistance and/or Glucose Intolerance Pathogenetic in the Development of a Reduced Incretin Effect |
- Incremental GLP-1 response during the mixed meal test. Assessed as AUC during the 4 hour test. [ Time Frame: In the mixed meal test ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 30 |
| Study Start Date: | November 2008 |
| Estimated Study Completion Date: | September 2009 |
| Estimated Primary Completion Date: | August 2009 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Dexamethasone |
Drug: Dexamethasone
2mg morning and night for 5 days.
|
Detailed Description:
In this study we are going to examine the incretin effect before and after the development of insulin resistance and/or glucose intolerance. The incretin effect is the increased insulin response seen after an oral as apposed to an intravenous glucose challenge with identical plasma glucose profiles. This insulin enhancing effect is greatly reduced in type 2 diabetes.
Since the development of type 2 diabetes is preceded by insulin resistance and glucose intolerance we wanted to examine the incretin effect in the early stages of type 2 diabetes.
To do this, we want to induce insulin resistance and/or glucose intolerance. This is achieved by 5 days of treatment with dexamethasone.
The incretin effect in this study will be examined by 3 investigations prior to the treatment and 3 days following the treatment.
Day 1: Oral glucose challenge with 75 g of glucose.
The subject is asked to drink 75g of glucose suspended in 300mL of water. During the 4 hours of the test, we draw blood at various times during the study to determine the concentration of: Glucose, GLP-1, GIP, Glucagon, Insulin and c-peptide.
Day 2: Intravenous glucose
We duplicate the glucose curve obtained from day 1. We also draw blood during this test to the same end as in day 1.
Day 3: Mixed meal.
The subjects are served a mixed meal. During this 4 hour test, we draw blood to examine the response to a standardized meal. The test involves sampling blood as described for the other days.
Eligibility| Ages Eligible for Study: | 20 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Caucasians >20 years
- Normal glucose tolerance as assessed by the WHO criteria
- First degree relative and at least 1 second degree relative with type 2 diabetes
- Normal haemoglobin
- Informed consent
Exclusion Criteria:
- Liver disease (ALAT/ASAT > 2 times normal value)
- Kidney disease (S-creatinin > 130uM and/or albuminuria)
- Heart disease (NYHA II, III or IV)
- Treatment with medicine that cannot be paused
- Pregnancy of breast feeding
Contacts and Locations| Contact: David H. Jensen, stud. med. | +45 35 31 50 84 | DJEN0051@regionh.bbh.dk |
| Contact: Thure Krarup, dr. med | +45 35 31 27 24 | TKRA0008@regionh.bbh.dk |
| Denmark | |
| Bispebjerg Hospital | Recruiting |
| Copenhagen, Denmark, 2300 | |
| Sub-Investigator: David H. Jensen, stud. med | |
| Principal Investigator: | Thure Krarup, dr. med. | Bispebjerg Hospital |
More Information
Publications:
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Thure Krarup, dr. med., Bispebjerg Hospital |
| ClinicalTrials.gov Identifier: | NCT00784745 History of Changes |
| Other Study ID Numbers: | H-D-2008-087 |
| Study First Received: | November 3, 2008 |
| Last Updated: | November 3, 2008 |
| Health Authority: | Denmark: Ethics Committee |
Keywords provided by University Hospital, Gentofte, Copenhagen:
|
incretin effect type 2 diabetes GLP-1 GIP dexamethasone |
Additional relevant MeSH terms:
|
Insulin Resistance Glucose Intolerance Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Hyperglycemia Dexamethasone acetate Dexamethasone Dexamethasone 21-phosphate BB 1101 Incretins Anti-Inflammatory Agents Therapeutic Uses Pharmacologic Actions |
Antiemetics Autonomic Agents Peripheral Nervous System Agents Physiological Effects of Drugs Central Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal Antineoplastic Agents Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on May 23, 2013